ClinicalTrials.gov record

Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP)

ClinicalTrials.gov ID: NCT04328961

Public ClinicalTrials.gov record NCT04328961. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 7, 2026, 7:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Efficacy of Hydroxychloroquine for Post-exposure Prophylaxis (PEP) to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Among Adults Exposed to Coronavirus Disease (COVID-19): a Blinded, Randomized Study

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a clinical study for the prevention of SARS-CoV-2 infection in adults exposed to the virus. This study will enroll up to 2000 asymptomatic men and women 18 to 80 years of age (inclusive) who are close contacts of persons with laboratory confirmed SARS-CoV-2 or clinically suspected COVID-19. Eligible participants will be enrolled and randomized to receive the intervention or placebo at the level of the household (all eligible participants in one household will receive the same intervention).

Study identification

NCT ID: NCT04328961
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2, Phase 3
Lead sponsor: University of Washington; Other
Enrollment: 943 participants

Conditions and interventions

Conditions

Interventions

Hydroxychloroquine Sulfate Drug
Ascorbic Acid Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 80 Years
Sex: All
Healthy volunteers: Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Mar 30, 2020
Primary completion: Sep 23, 2020
Completion: Oct 7, 2020
Last update posted: Dec 15, 2021

2020

United States locations

U.S. sites: 8
U.S. states: 6
U.S. cities: 7

Facility	City	State	ZIP	Site status
University of California Los Angeles	Los Angeles	California	90095	—
Tulane	New Orleans	Louisiana	70118	—
University of Maryland, Baltimore	Baltimore	Maryland	21201	—
Boston University	Boston	Massachusetts	02215	—
NYU Langone Health	New York	New York	10016	—
SUNY Upstate Medical University	Syracuse	New York	13210	—
University of Washington, Coordinating Center	Seattle	Washington	98104	—
UW Virology Research Clinic	Seattle	Washington	98104	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT04328961, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Dec 15, 2021 · Synced Sep 7, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04328961 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →